Implant‐prosthetic treatment in patients with oral lichen planus: A systematic review

Abstract

Aims: This review is aiming on identifying the ideal implant-prosthetic treatment design in patients with OLP. Methods and Results: A systematic review was conducted using four electronic databases; Medline (PubMed), Cochrane library, DOAJ and SCOPUS, following the PRISMA statement recommendations to answer the PICO question: "which implant-prosthetic treatment design is most useful to ensure implant survival in OLP patients?". The study was pre-registered in PROSPERO (CRD 42020220102).Included articles quality was assessed using the "Newcastle-Ottawa scale" and the JBI critical appraisal tool for case series. No article was found specifically designed to analyze the prosthetic influence on implant survival in OLP patients.Despite, information about implant-prostheses in studies designed with other goals was compiled. Eight articles that involved 141 patients and 341 implants were finally selected. The weighted mean follow-up was 38 months and the weighted mean survival of the implants 98.9%. No statistical differences were observed between cemented or screw retained prostheses and the materials employed or the technology to manufacture the prostheses. Conclusion:The influence of prosthetic design on implant survival in OLP patients is still poorly understood, but important clinical recommendations can be drawn. The strength of evidence was grade 3b (CEBM) or low (GRADE).

Dental Implant Treatment in Patients Suffering from Oral Lichen Planus: A Narrative Review

“…When the results of the abovementioned study and of the cases that developed oral squamous cell carcinoma were not considered, the dental implant failure rate in OLP patients was as low as 2.7% after a follow-up of five years, which is similar to populations without OLP (~2%) [ 30 ]. Recent systematic reviews reported a survival rate of dental implants placed in OLP patients of 98.9% after 38 months, 97.3% after 5 years, or 95.8% during a follow-up period ranging from 1 to 13 years [ 20 , 30 , 31 ]. The results from other systematic reviews and meta-analyses evaluating the outcomes of dental implants in OLP patients are provided in Table 2 [ 20 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ].…”

“…Recent systematic reviews reported a survival rate of dental implants placed in OLP patients of 98.9% after 38 months, 97.3% after 5 years, or 95.8% during a follow-up period ranging from 1 to 13 years [ 20 , 30 , 31 ]. The results from other systematic reviews and meta-analyses evaluating the outcomes of dental implants in OLP patients are provided in Table 2 [ 20 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ].…”

“…Conventional prosthetic treatment options and improvements in patients’ quality of life following therapy might be limited due to the effects of the underlying disease. In a very recent systematic review, Anitua et al [ 31 ] made some clinical recommendations for implant-prosthetic treatment in patients with OLP. Fixed implant-supported prostheses may prevent the friction or trauma caused by conventional removable mucogingival prostheses or overdentures.…”

“…The use of transmucosal abutments may allow an epithelium to face the most biocompatible materials with optimal superficial characteristics. Regarding the most suitable materials for OLP patients, the choice of titanium for the abutments and the metal suprastructure of restorations may be recommended [ 31 ]. No data were reported on the usage of zirconia (ZrO 2 ) abutments in this systematic review.…”

“…Recent systematic reviews reported a survival rate of dental implants placed in OLP patients of 98.9% after 38 months, 97.3% after 5 years, or 95.8% during a follow-up period ranging from 1 to 13 years [20,30,31]. The results from other systematic reviews and meta-analyses evaluating the outcomes of dental implants in OLP patients are provided in Table 2 [20,[30][31][32][33][34][35][36][37]. "This review suggested that dental implants may be considered as a safe and viable therapeutic option in the management of edentulous patients suffering from autoimmune diseases.…”